Literature DB >> 16962361

Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations.

Lise Musset1, Olivier Bouchaud, Sophie Matheron, Laurent Massias, Jacques Le Bras.   

Abstract

Plasmodium falciparum resistance to atovaquone-proguanil has so far been associated with Y268S or Y268N mutations in cytochrome b, although these changes were identified in only seven of the 11 treatment failures. Here, we describe 10 new cases of atovaquone-proguanil treatment failures among which the parasite resistance was confirmed in six cases, either by identifying correct plasma drug concentrations or by observing in vitro atovaquone resistance. Resistance was consistently associated with codon 268 mutations (Y268S or a previously unidentified mutation, Y268C). Notably, mutations were not detected before the treatment but only after the drug exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16962361     DOI: 10.1016/j.micinf.2006.07.011

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  49 in total

1.  First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.

Authors:  Helene Savini; Hervé Bogreau; Lionel Bertaux; Housem Bouchiba; Philippe Kraemer; Daniel Parzy; Eric Garnotel; Christophe Rogier; Fabrice Simon; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

2.  Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.

Authors:  Luicer A Ingasia; Hoseah M Akala; Mabel O Imbuga; Benjamin H Opot; Fredrick L Eyase; Jacob D Johnson; Wallace D Bulimo; Edwin Kamau
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

3.  Selection of Plasmodium falciparum cytochrome B mutants by putative PfNDH2 inhibitors.

Authors:  Kristin D Lane; Jianbing Mu; Jinghua Lu; Sean T Windle; Anna Liu; Peter D Sun; Thomas E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

Review 4.  Current therapies and future possibilities for drug development against liver-stage malaria.

Authors:  Rene Raphemot; Dora Posfai; Emily R Derbyshire
Journal:  J Clin Invest       Date:  2016-06-01       Impact factor: 14.808

5.  Saccharomyces cerevisiae-based mutational analysis of the bc1 complex Qo site residue 279 to study the trade-off between atovaquone resistance and function.

Authors:  Zehua Song; Jérôme Clain; Bogdan I Iorga; Zhou Yi; Nicholas Fisher; Brigitte Meunier
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

6.  Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy.

Authors:  Allison M Stickles; Li-Min Ting; Joanne M Morrisey; Yuexin Li; Michael W Mather; Erin Meermeier; April M Pershing; Isaac P Forquer; Galen P Miley; Sovitj Pou; Rolf W Winter; David J Hinrichs; Jane X Kelly; Kami Kim; Akhil B Vaidya; Michael K Riscoe; Aaron Nilsen
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

Review 7.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

Review 8.  In vitro selection of Plasmodium falciparum drug-resistant parasite lines.

Authors:  Alexis Nzila; Leah Mwai
Journal:  J Antimicrob Chemother       Date:  2009-12-18       Impact factor: 5.790

9.  Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.

Authors:  Ana Afonso; Zoraima Neto; Helena Castro; Dinora Lopes; Ana C Alves; Ana M Tomás; Virgílio D Rosário
Journal:  Malar J       Date:  2010-05-21       Impact factor: 2.979

10.  Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.

Authors:  Colin J Sutherland; Matt Laundy; Nicholas Price; Martina Burke; Quinton L Fivelman; Geoffrey Pasvol; John L Klein; Peter L Chiodini
Journal:  Malar J       Date:  2008-11-20       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.